NEW ANTIPLATELET DRUGS. PART 2
Antiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/940 |
| _version_ | 1826949757132603392 |
|---|---|
| author | A. B. Sumarokov |
| author_facet | A. B. Sumarokov |
| author_sort | A. B. Sumarokov |
| collection | DOAJ |
| description | Antiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very limited. Pharmacology of antiplatelet drug has been developing rapidly. New antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors, thrombin receptors inhibitors. Clinical pharmacology of these drugs is different. Practitioner should know their specifics to avoid the development of iatrogenic complications. |
| first_indexed | 2024-03-08T14:03:52Z |
| format | Article |
| id | doaj.art-4120e402f0a14827ae993922635829e1 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:19:50Z |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-4120e402f0a14827ae993922635829e12024-12-04T11:48:08ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-017563764310.20996/1819-6446-2011-7-5-637-643939NEW ANTIPLATELET DRUGS. PART 2A. B. Sumarokov0Institute for Cardiology named after A.L. Mjasnikov , Russian Cardiology Research and Production ComplexAntiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very limited. Pharmacology of antiplatelet drug has been developing rapidly. New antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors, thrombin receptors inhibitors. Clinical pharmacology of these drugs is different. Practitioner should know their specifics to avoid the development of iatrogenic complications.https://www.rpcardio.online/jour/article/view/940disaggregantsprasugrelticagrelorelinogrel inhibitorsthromboxane receptor inhibitorsthrombin receptor inhibitors |
| spellingShingle | A. B. Sumarokov NEW ANTIPLATELET DRUGS. PART 2 Рациональная фармакотерапия в кардиологии disaggregants prasugrel ticagrelor elinogrel inhibitors thromboxane receptor inhibitors thrombin receptor inhibitors |
| title | NEW ANTIPLATELET DRUGS. PART 2 |
| title_full | NEW ANTIPLATELET DRUGS. PART 2 |
| title_fullStr | NEW ANTIPLATELET DRUGS. PART 2 |
| title_full_unstemmed | NEW ANTIPLATELET DRUGS. PART 2 |
| title_short | NEW ANTIPLATELET DRUGS. PART 2 |
| title_sort | new antiplatelet drugs part 2 |
| topic | disaggregants prasugrel ticagrelor elinogrel inhibitors thromboxane receptor inhibitors thrombin receptor inhibitors |
| url | https://www.rpcardio.online/jour/article/view/940 |
| work_keys_str_mv | AT absumarokov newantiplateletdrugspart2 |